Filing summary
Entity clarification: The supplied filing is Tivic Health Systems, Inc. (Nasdaq: TIVC), not Valion Bio, Inc. It is the Form 10-K for the fiscal year ended December 31, 2022; it does not provide standalone fourth-quarter results.
Business context and reporting period
Tivic develops and commercializes non-invasive bioelectronic medical devices. Its principal commercial product, ClearUP, is an FDA-cleared, cash-pay device for sinus pain and congestion, sold through its website and online retail channels. The company is also researching devices for post-sinus-surgery pain and migraine, which remain in development and require further study and regulatory clearances.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $1.84 million | $1.26 million |
| Gross profit (loss) | $299,000 | $(38,000) |
| Gross margin | 16.3% | (3.0%) |
| Operating expenses | $10.40 million | $5.60 million |
| Operating loss | $(10.10) million | $(5.63) million |
| Net loss | $(10.10) million | $(8.49) million |
| Cash used in operating activities | $8.92 million | $5.61 million |
At year-end 2022, cash and cash equivalents were $3.52 million, working capital was approximately $3.4 million, accumulated deficit was $29.6 million, and total liabilities were $2.23 million. Operating lease liabilities totaled $530,000. The filing also discloses a $450,000 outstanding balance on financing for D&O insurance premiums; its presentation is not separately clear in the balance-sheet liability lines. Prior convertible notes had converted to equity in 2021.
Changes versus the prior year
- Revenue rose 46%, with total unit sales up 22%. Direct-to-consumer revenue increased 114% to $1.64 million, while reseller revenue fell 32% to $416,000 following the termination of less-profitable channels.
- Gross profit improved from a loss to $299,000, but variable product cost per unit increased from $82.46 to $87.04, which the company attributed in part to component price increases and supply constraints.
- Operating expenses increased 86% to $10.40 million, including higher research and development, marketing, public-company costs, insurance, and costs related to the proposed Reliefband acquisition.
- Operating cash use increased by $3.31 million year over year. Year-end cash declined from $12.98 million to $3.52 million.
Outlook, risks and unusual items
- Going concern: Management and the auditor state that recurring losses, negative operating cash flows, and available resources raise substantial doubt about the company’s ability to continue as a going concern within one year of the financial statements’ issuance. Management expects significant losses for at least the next two years and says additional financing will be needed; availability and terms are uncertain.
- Subsequent financing: A February 2023 public offering sold 20 million shares at $0.25 per share, producing approximately $3.6 million net proceeds, and included warrants for 1 million additional shares. This materially increased the share count and diluted existing holders.
- Nasdaq listing: Nasdaq notified the company in January 2023 that its share price did not meet the $1 minimum bid requirement. The stated compliance deadline was July 25, 2023; the company expected to implement a reverse stock split if needed.
- Internal controls: Management reported a material weakness in internal control over financial reporting, attributed to the small finance team and recently implemented procedures. Management concluded controls were not effective at year-end 2022.
- Operations and development: Supply-chain constraints in 2022 caused higher costs, longer lead times, and component shortages. The company expects new manufacturing and fulfillment arrangements to reduce costs, but provides no quantified savings or financial guidance. The proposed $33.5 million Reliefband acquisition was mutually terminated in December 2022 due to market conditions and difficulty obtaining financing.
- Regulatory and commercial risks: ClearUP’s EU CE certificate expires in June 2024, and renewal under EU medical-device regulations was in progress. ClearUP is not reimbursed by government or private healthcare programs. No material legal proceedings were reported.
Most important facts to verify
- How the February 2023 offering proceeds affect cash runway, and whether additional capital is required beyond that financing.
- The classification and repayment terms of the disclosed $450,000 insurance-premium financing balance.
- Progress in remediating the material weakness and whether subsequent filings report effective internal controls.
- Nasdaq bid-price compliance and any reverse stock split or delisting developments after the filing date.
- Whether EU CE certification was renewed and whether new manufacturing arrangements deliver the expected cost reductions.